Common Stock, $0.001 par value
- Symbol
- SBEV
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Historical · closed Jun 4, 2026
Current Report · Items 7.01, 9.01 · 8-K
Endovia Health Sciences, Inc.
EDVANYSE_AMERICANEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 6, 2026, Splash Beverage Group, Inc. issued a press release announcing an exclusive global licensing agreement with Argent BioPharma Limited (ASX/LSE: RGT). A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.…
Company context
The Company is a Nevada corporation that was historically seeking to identify, acquire, and build early stage or under-valued beverage brands that have strong growth potential within its distribution system. During the current fiscal year beginning January 1, 2026, the Company has moved away from beverages and is focusing on the cannabinoid and health and wellness economy businesses.
Current securities
Registered securities in this filing
SPLASH BEVERAGE GROUP, INC. · 8-K · Filed 2026-07-06
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On July 6, 2026, Splash Beverage Group, Inc. issued
a press release announcing an exclusive global licensing agreement with Argent BioPharma Limited (ASX/LSE: RGT). A copy of the press release
is furnished as Exhibit 99.1 of this Current Report on Form 8-K.
The information in this Item 7.01 (including Exhibit
99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of
the Company under the Securities Act of 1933 or the Exchange Act.
Filed exhibits (1)
EX-99.1 2 e7759_ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL FORT LAUDERDALE, FL - July 6, 2026 - Splash Beverage Group, Inc. (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX/LSE: RGT) for CannEpil®, a proprietary, cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy (DRE) in multiple European countries. CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been made available in multiple international markets, including Ireland, the United Kingdom, Germany and Australia. The therapy is manufactured under European Union Good Manufacturing Practice (EU-GMP) standards. Drug-resistant epilepsy affects approximately 30% of epilepsy patients worldwide and remains one of the most significant unmet needs in neurology, with millions of patients continuing to experience uncontrolled seizures despite currently available therapies. “The acquisition of the exclusive global rig…
Open exhibit ↗